Nuveen LLC Takes $302,000 Position in Alto Neuroscience, Inc. $ANRO

Key Points

• Nuveen LLC has acquired a new position in Alto Neuroscience, Inc. with a purchase of 139,953 shares valued at approximately $302,000, equating to about 0.52% ownership of the company.
• Analysts have mixed ratings on Alto Neuroscience, with Wedbush giving a neutral rating and a price target of $4.00, while HC Wainwright maintains a buy rating with a price target of $10.00.
• Alto Neuroscience's recent earnings report showed a loss of ($0.65) per share, missing the consensus estimate, as the company operates in clinical trials for treatments related to major depressive disorder and post-traumatic stress disorder.

Nuveen LLC acquired a new position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 139,953 shares of the company's stock, valued at approximately $302,000. Nuveen LLC owned approximately 0.52% of Alto Neuroscience as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the company. Wells Fargo & Company MN boosted its holdings in Alto Neuroscience by 40.0% in the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock valued at $46,000 after purchasing an additional 3,139 shares during the period. Deutsche Bank AG raised its holdings in shares of Alto Neuroscience by 31.3% in the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock valued at $64,000 after acquiring an additional 3,629 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock valued at $79,000 after acquiring an additional 7,783 shares in the last quarter. Barclays PLC raised its holdings in shares of Alto Neuroscience by 34.5% in the 4th quarter. Barclays PLC now owns 39,807 shares of the company's stock valued at $168,000 after acquiring an additional 10,208 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Alto Neuroscience by 27.2% in the 4th quarter. Wellington Management Group LLP now owns 77,146 shares of the company's stock valued at $326,000 after acquiring an additional 16,510 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Wedbush reaffirmed a "neutral" rating and issued a $4.00 price target on shares of Alto Neuroscience in a report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Alto Neuroscience in a report on Monday, August 18th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

Alto Neuroscience Stock Performance

Alto Neuroscience stock opened at $3.65 on Friday. The company has a quick ratio of 18.43, a current ratio of 18.43 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $98.71 million, a PE ratio of -1.53 and a beta of 1.91. The firm has a fifty day simple moving average of $3.10 and a two-hundred day simple moving average of $2.75. Alto Neuroscience, Inc. has a twelve month low of $1.60 and a twelve month high of $15.04.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Research analysts expect that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

Want to see what other hedge funds are holding ANRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alto Neuroscience, Inc. (NYSE:ANRO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.